NASDAQ:ELYM - Free Report ) by 12.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,180,000 shares of the company's stock after buying an additional 241,737 shares during the period. Eliem Therapeutics accounts for approximately 4.4% of BML Capital Management LLC's investment portfolio, making the stock its 6th largest position. BML Capital Management LLC owned 7.91% of Eliem Therapeutics worth $5,886,000 at the end of the most recent quarter.
Get Eliem Therapeutics alerts:
Sign Up
Separately, Cerity Partners LLC purchased a new position in shares of Eliem Therapeutics during the 4th quarter worth approximately $37,000. Institutional investors own 69.76% of the company's stock.
Eliem Therapeutics Price Performance Shares of NASDAQ:ELYM traded down $0.09 during mid-day trading on Wednesday, reaching $3.66. 113,513 shares of the company were exchanged, compared to its average volume of 570,295. The firm has a market cap of $101.46 million, a price-to-earnings ratio of -2.49 and a beta of 0.51. The firm's 50-day simple moving average is $3.02 and its 200 day simple moving average is $2.79. Eliem Therapeutics, Inc. has a 1 year low of $2.34 and a 1 year high of $5.19.
Eliem Therapeutics Profile (
Free Report )
Eliem Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial.
Further Reading
Before you consider Eliem Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eliem Therapeutics wasn't on the list.
While Eliem Therapeutics currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
